| scholarly article | Q13442814 |
| P2093 | author name string | Alfredo Velena | |
| Hong Cao | |||
| Mira Jung | |||
| Zacharoula Konsoula | |||
| P2860 | cites work | Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells | Q46492826 |
| Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies | Q48150989 | ||
| Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation | Q57782739 | ||
| Prostate cancer epidemiology | Q73138981 | ||
| Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors | Q74044270 | ||
| Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors | Q81405772 | ||
| Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors | Q81610242 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines | Q28366390 | ||
| Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer | Q29615649 | ||
| Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. | Q33255121 | ||
| Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies | Q33375294 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Histone-deacetylase inhibitors: novel drugs for the treatment of cancer | Q34743301 | ||
| HDAC inhibitors for the treatment of cancer | Q35648783 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| Histone deacetylase inhibitors open new doors in cancer therapy | Q35864048 | ||
| The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation. | Q36371074 | ||
| Prostate stem cells: from development to cancer | Q36510062 | ||
| In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors | Q36931722 | ||
| Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells | Q37011590 | ||
| HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats | Q37120410 | ||
| Clinical studies of histone deacetylase inhibitors. | Q37512917 | ||
| Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. | Q39026671 | ||
| Correlation of in vitro cytotoxicity with paracellular permeability in mortal rat intestinal cells | Q40246907 | ||
| A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. | Q40477758 | ||
| Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors | Q40669828 | ||
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells | Q40765366 | ||
| Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line | Q41180892 | ||
| Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes | Q42814677 | ||
| A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule | Q43763013 | ||
| Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates | Q43879025 | ||
| Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors | Q44086974 | ||
| Thiol-based SAHA analogues as potent histone deacetylase inhibitors | Q44900745 | ||
| Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design | Q45189994 | ||
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma | Q46455509 | ||
| P433 | issue | 10 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 2844-2851 | |
| P577 | publication date | 2009-09-29 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors | |
| P478 | volume | 8 |
| Q38435029 | Functional Roles of Acetylated Histone Marks at Mouse Meiotic Recombination Hot Spots |
| Q37929048 | Histone deacetylase inhibitor: antineoplastic agent and radiation modulator |
| Q37190538 | Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease |
| Q51034578 | Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects. |
| Q38071321 | Toxicological and metabolic considerations for histone deacetylase inhibitors |
| Q89529397 | Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer |
| Q41115468 | Valproic acid attenuates the expression of pro-inflammatory cytokines lipopolysaccharide-treated canine peripheral blood mononuclear cells (in vitro) and in a canine endotoxemia model (in vivo). |
Search more.